NeutriSci International Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Glen Rehman
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 1600 – 609 Granville Street Vancouver BC Canada V7Y 1C3
- IPO Date
- Sep 7, 2016
- Website
- neutrisci.com
- Similar Companies
- Business
- NeutriSci International Inc. develops, formulates, produces, and markets nutraceutical products for B2B partners in the health and wellness industry; core offerings include neuenergy energy tablets for enhanced focus and mental clarity, effervescent functional mushroom tablets, and sublingual tabs such as Dablets and Zenstix utilizing patent-pending Cryolization Technology for rapid bloodstream delivery of natural ingredients including cannabinoids; the company also provides contract manufacturing, co-branding, private label services, and product development expertise incorporating proprietary IP. NeutriSci International operates production and research facilities including a dedicated site in Las Vegas, Nevada, with scalability for global distribution through retail storefronts, online channels, convenience stores, chain drug outlets, mass market retailers, and supermarkets; it serves markets in Canada, the United States, Germany, Japan, Europe, Asia, South America, and Australia. Founded in 2009 and headquartered in Vancouver, Canada, the company maintains strategic partnerships with entities including Tabletz LLC for Japanese distribution, THIC for European market entry, Cryopharm, LaSanta Botanicals, Nutritional High, Naturally Splendid, Thai Freeze Dry, and Scientus Pharma; recent developments encompass voluntary delisting from OTCQB in February 2022 to redirect capital, ongoing global B2B expansion, new product pipelines, and facility optimizations for higher margins.
NeutriSci Receives Additional Purchase Order and Deposit from Tabletz Distribution Partner
NeutriSci Arranges Strategic Financing with Tabletz and Exercise of Warrants
Neutrisci Provides Update on Tabletz Developments
Neutrisci Provides Update on Tabletz and Previously Announced Project Development
NeutriSci Provides Update On Biople Product Launch In Japan
Neutrisci Ships Tabletz Rush Order to #1 CBD Retailer in Japan
NeutriSci Completes R&D and Expands Product Selection to Include Beverages
NeutriSci and Pacwest Announce Technology and IP Arrangement for R&D Product Development
Neutrisci Announces Successful Completion of Phase 1 R&D Development of a Cannabinol Product
Neutrisci Receives Additional Order for Japanese Market
Neutrisci Announces New State-Of-The-Art Production and Research Facility in Las Vegas, Nevada, USA
NeutriSci: Harmonized Code Approval Received by TABLETZ LLC., in Japan